<DOC>
	<DOC>NCT00312013</DOC>
	<brief_summary>This study will evaluate the effects of nadroparin on survival and disease progression in patients with hormone-refractory prostate cancer (HRPC), locally advanced pancreatic cancer or non-small-cell lung carcinoma (NSCLC).</brief_summary>
	<brief_title>Effects Of Nadroparin In Patients With Lung, Pancreas Or Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Nadroparin</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<criteria>Inclusion criteria: Hormone refractory prostate cancer within 6 months of diagnosis, OR locally advanced (nonmetastasized) pancreatic cancer within 3 months of diagnosis, OR nonsmallcell lung cancer within 3 months of stage IIIB. Exclusion criteria: Life expectancy of &lt;3 months. Poor performance status (Karnofsky &lt;60). Need to be on anticoagulants. Use of nadroparin (a low molecular weight heparin) for any reason including a history of heparininduced thrombocytopenia. Have brain metastasis. At a high risk of bleeding or have a platelet count &lt;50,000/mm3. Have very poor kidney function.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>low molecular weight heparin</keyword>
	<keyword>nadroparin</keyword>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>cancer survival</keyword>
	<keyword>prostate cancer</keyword>
	<keyword>pancreatic cancer</keyword>
</DOC>